ClinicalTrials.gg
Active, not recruitingNCT06105619Updated Jan 20, 2026

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

A Phase 2/3 interventional study of PLB1001 and Temozolomide in Glioblastoma, sponsored by Beijing Pearl Biotechnology Limited Liability Company. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Beijing Pearl Biotechnology Limited Liability Company · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Oct 2018, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Glioblastoma with a site in China — 73 open to participants now, 80 under way, 7 of them phase 3. Glioblastoma · China.

Enrollment
31st of 127
84 · median 36
Started
2018
with 3 others
Phase 2/3
2 of 142
1 open now
Primary completion
2023-04
later than 1 of 79 live
Registered
85th of 142
by date

Among the 142 studies in Glioblastoma with a site in China, this one is the 31st largest by enrollment of the 127 interventional ones that give a count, is one of 4 that started in 2018, is one of 2 in phase 2/3, reaches primary completion later than 1 of the 79 other live ones, and was the 85th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

73 of the 142 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are:

  1. To evaluate overall survival (OS) in the treatment of secondary glioblasts with positive recurrence of PTPRZ1-MET (ZM) fusion gene by PLB1001 Enteric Capsules.
  2. To evaluate if it is safety and tolerant in the treatment of secondary glioblasts with positive recurrence of PTPRZ1-MET (ZM) fusion gene by PLB1001 Enteric Capsules.

Participants will

  1. Be given PLB1001 300mg BID,oral who were randomly assigned in test group.
  2. Be given Temozolomide capsules ,oral, who were randomly assigned in control group.
  3. Be given EP, ivgtt, who were randomly assigned in control group.
Read the detailed description

84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene will be randomly divided into group A (receive vebreltinib) or group B ( receive investigator choose), and the randomize ratio will be 1:1, patients in group A will receive PLB1001 300mg Bid, 28days/cycle. Patients in group B will receive temozolomide (100-150mg/m2/d, 7 days 1 to7 and days 15 to 22 of each 28-day cycle ) or cisplatin+etoposide(cisplatin:80-100mg/m2/3 days, 28days/cycle; etoposide:100mg/m2/d, 3days, 28 days/cycle).

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed secondary glioblastoma,or glioblastoma with IDH mutantation
  2. Must have evidence of PRPRZ1-MET fusion gene positivity from the result of molecular pre-screening evaluations
  3. Prior treatment with temozolomide and radiotherapy
  4. Stable or decreasing dose of within 5 days prior to the first dose
  5. count≥75×109/L,Neutrophilic granulocyte count≥1.5×109/L, >90g/L, or ALT \< 3 times the lab's upper normal limit,Serum creatinine \< 1.5 times the lab's upper normal limit,≤2.0
  6. performance score ≥ 60%
  7. Pregnant or nursing women
  8. Written consent

Exclusion criteria

Exclusion Criteria:

  1. Previous or current treatment with a c-Met inhibitor or HGF-targeting therapy
  2. Received antibody anti-tumor drug within 30 days before enrollment
  3. Previous treatment with Camustine sustained release implant
  4. The subject is unable to undergo MRI scan
  5. Patients with active bleeding were found by brain CT or MRI scan before enrollment
  6. Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) 150 mm Hg and/or Diastolic Blood Pressure (DBP) ≥100 mm Hg
  7. Major surgery within 4 weeks prior to first dose of PLB1001
  8. Pregnant or nursing women
  9. Involved in other clinical trials \<30 days prior to first dose
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    PLB1001

    Subjects will receive 300mg of PLB1001 twice daily in cycles of 4 weeks duration until death or adverse event(AE) leading to discontinuation

    Drug: PLB1001

  • Active comparator
    Temozolomide or Cisplatin combined with etoposide

    Investigators can choose one of two treatments 1. Dose density of temozolomide:100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle 2. Cisplatin combined with etoposide:Cisplatin,80-100mg/m2/3 days,28 days/cycle.etoposide, 100mg/m2/d,3 days,28 days/cycle

    Drug: Temozolomide · Drug: Cisplatin combined with Etoposide

Interventions

  • PLB1001 is a capsule in the form of 300mg,twice daily.

    Also known as: Vebreltinib

  • 100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle

  • DrugCisplatin combined with Etoposide

    Drug pages: Cisplatin · Etoposide

    Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle

06

What researchers measure

Primary outcomes

  1. Overall survival(OS)

    Overall survival is defined as the time(in months)from random to the date of death.

    Time frame: 5 years

Secondary outcomes

  1. Objective Response Rate Evaluated by Investigator(ORR)

    Objective response rate will be determined according to response assessment in neuro-oncology(RANO).

    Time frame: 5 years

  2. Progression Free Survival evaluated by Investigator(PFS)

    Progression Free Survival is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD or death due to any cause.

    Time frame: 5 years

  3. Quality of Life Assessment EORTC-QLQ-C30

    The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item scales and single-item measures. These include the Physical Functioning Scale and four more functional scales (role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status / QoL scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and difficulties). Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." The method for scoring these scales is: 1. Estimate the average of the items that contribute to the scale; this is the raw score. 2. Use a linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: 5 years

  4. Karnofsky Performance Status score

    improved is defined as KPS increases \>10 after treatment; worsen is defined as KPS decreases \>10; stable is defined as KPS changes ≤10.

    Time frame: 5 years

  5. Quality of Life Assessment EORTC-QLQ-BN20

    The EORTC-QLQ-BN20 covers future uncertainty, visual disorder, motor dysfunction, communication deficit, headache, seizures, drowsiness, hair loss, itching, difficulty with bladder control, and weakness of both legs. Patients respond by self-report, with most items rated on a 4-point scale, from 1 "not at all" to 4 "very much", except for the two global health status/quality of life items, which are measured on a 7-point Likert scale ("very poor" through "excellent"). The method for scoring these scales is: 1. Estimate the average of the items that contribute to the scale; this is the raw score. 2. Use a linear transformation to standardize the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Apr 2023, 53 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 27, 2023
StartActual
Oct 8, 2018
Primary completionActual
Apr 1, 2023
CompletionEst.
Dec 31, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06105619
Lead sponsor
Beijing Pearl Biotechnology Limited Liability Company
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Oct 8, 2018
Primary completion
Apr 1, 2023
Completion
Dec 31, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Wenbin Li
principal investigator · Beijing Tiantan Hospital
Xiaoguang Qiu
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vebreltinib

Start the discussion